Champions Oncology, Inc. (CSBR)

Over the past six months, Champions Oncology, Inc.'s stock price has decreased by 10.14%. On April 9, 2026, Champions Oncology announced plans to present new data at AACR 2026. On March 30, 2026, Brian Alexander was appointed to the Board. On March 12, 2026, the company reported its financial results for the third quarter of fiscal year 2026, with total revenue of $16.6 million and a GAAP loss from operations of approximately $275,000. On December 15, 2025, Champions Oncology reported record quarterly service revenue of $14.9 million.

Demand seasonality for Champions Oncology's products and services is characterized by fluctuations rather than a predictable seasonal pattern. The company's quarterly revenue can vary significantly depending on the timing of studies and the achievement of completion milestones. Revenue generated from Lumin Bioinformatics is expected to vary from quarter to quarter as the platform develops. The company's overall success is also closely tied to the research and development (R&D) spending of its clients.

Champions Oncology, Inc. is a technology-enabled research company in the Healthcare sector, specifically Biotechnology and Medical Research. It provides technology solutions for drug discovery and development, primarily in the United States, offering the TumorGraft technology platform for personalized cancer care and translational oncology solutions. The company also provides Lumin Bioinformatics, an oncology data-driven software program, and engages in drug discovery and development.

Champions Oncology has a global presence with clinical sites, laboratories, and a scientific team distributed around the world. The company procures its TumorGrafts through agreements with various institutions in the U.S. and overseas. Its headquarters are located in Hackensack, New Jersey, with a business address also in Baltimore, Maryland.

Champions Oncology's reports have an aggregate usefulness score of 4.8 out of 5.0 based on 152 reviews, suggesting a generally positive perception of their documentation and information. No specific events negatively or positively impacting the company's brand reputation beyond general business performance and announcements were prominently reported in the past year.

The ownership structure of Champions Oncology (CSBR) includes institutional investors (0.92% to 6.23%), insiders (14.82%), and public/individual investors (78.95%). Major institutional owners include Battery Management Corp., NEA Management Company, LLC, Vanguard Group Inc, Tocqueville Asset Management L.p., Morgan Stanley, Renaissance Technologies Llc, BlackRock, Inc., Mink Brook Asset Management LLC, Geode Capital Management, Llc, and Northern Trust Corp. Joel Ackerman owns the most shares among individual investors.